cncpt-artikel_lb_atf
ASH 2023: Oral Decitabine-Cedazuridine Tablet Shows Promise for AML Treatment in Phase III Study
A phase III study unveils that an oral fixed-dose combination of decitabine and cedazuridine, offers a new, effective oral treatment route for AML patients unable to undergo standard chemotherapy.